Drug Profile
Ficlatuzumab - AVEO Oncology
Alternative Names: anti-HGF IgG1 mAb; Anti-HGF mAb; AV-299; Ficla; HFG MAb; SCH-900105Latest Information Update: 29 Nov 2023
Price :
$50
*
At a glance
- Originator AVEO Pharmaceuticals
- Developer AVEO Oncology; AVEO Pharmaceuticals; Biodesix; Dana-Farber Cancer Institute; National Cancer Institute (USA); University of Arizona Cancer Center
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Hepatocyte growth factor inhibitors; Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Squamous cell cancer
- Phase II Acute myeloid leukaemia; Non-small cell lung cancer; Pancreatic cancer
- No development reported Lymphoma; Multiple myeloma; Solid tumours
- Discontinued Glioblastoma
Most Recent Events
- 18 Nov 2023 Phase-III clinical trials in Squamous cell cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease, Recurrent) in USA (IV) (NCT06064877)
- 22 Jun 2022 AVEO Oncology and Eli Lilly and Company enters into a clinical trial collaboration and supply agreement for the evaluation of ficlatuzumab in combination with cetuximab for the treatment of head and neck squamous cell cancer
- 05 Apr 2022 AVEO in collaboration with University of Arizona Cancer Center, completes a phase II trial in Squamous cell carcinoma (Monotherapy, Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03422536)